Cargando…
Antioxidant Therapy in Cancer: Rationale and Progress
Cancer is characterized by increased oxidative stress, an imbalance between reactive oxygen species (ROS) and antioxidants. Enhanced ROS accumulation, as a result of metabolic disturbances and signaling aberrations, can promote carcinogenesis and malignant progression by inducing gene mutations and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220137/ https://www.ncbi.nlm.nih.gov/pubmed/35740025 http://dx.doi.org/10.3390/antiox11061128 |
_version_ | 1784732298423304192 |
---|---|
author | Luo, Maochao Zhou, Li Huang, Zhao Li, Bowen Nice, Edouard C. Xu, Jia Huang, Canhua |
author_facet | Luo, Maochao Zhou, Li Huang, Zhao Li, Bowen Nice, Edouard C. Xu, Jia Huang, Canhua |
author_sort | Luo, Maochao |
collection | PubMed |
description | Cancer is characterized by increased oxidative stress, an imbalance between reactive oxygen species (ROS) and antioxidants. Enhanced ROS accumulation, as a result of metabolic disturbances and signaling aberrations, can promote carcinogenesis and malignant progression by inducing gene mutations and activating pro-oncogenic signaling, providing a possible rationale for targeting oxidative stress in cancer treatment. While numerous antioxidants have demonstrated therapeutic potential, their clinical efficacy in cancer remains unproven. Here, we review the rationale for, and recent advances in, pre-clinical and clinical research on antioxidant therapy in cancer, including targeting ROS with nonenzymatic antioxidants, such as NRF2 activators, vitamins, N-acetylcysteine and GSH esters, or targeting ROS with enzymatic antioxidants, such as NOX inhibitors and SOD mimics. In addition, we will offer insights into prospective therapeutic options for improving the effectiveness of antioxidant therapy, which may expand its applications in clinical cancer treatment. |
format | Online Article Text |
id | pubmed-9220137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92201372022-06-24 Antioxidant Therapy in Cancer: Rationale and Progress Luo, Maochao Zhou, Li Huang, Zhao Li, Bowen Nice, Edouard C. Xu, Jia Huang, Canhua Antioxidants (Basel) Review Cancer is characterized by increased oxidative stress, an imbalance between reactive oxygen species (ROS) and antioxidants. Enhanced ROS accumulation, as a result of metabolic disturbances and signaling aberrations, can promote carcinogenesis and malignant progression by inducing gene mutations and activating pro-oncogenic signaling, providing a possible rationale for targeting oxidative stress in cancer treatment. While numerous antioxidants have demonstrated therapeutic potential, their clinical efficacy in cancer remains unproven. Here, we review the rationale for, and recent advances in, pre-clinical and clinical research on antioxidant therapy in cancer, including targeting ROS with nonenzymatic antioxidants, such as NRF2 activators, vitamins, N-acetylcysteine and GSH esters, or targeting ROS with enzymatic antioxidants, such as NOX inhibitors and SOD mimics. In addition, we will offer insights into prospective therapeutic options for improving the effectiveness of antioxidant therapy, which may expand its applications in clinical cancer treatment. MDPI 2022-06-08 /pmc/articles/PMC9220137/ /pubmed/35740025 http://dx.doi.org/10.3390/antiox11061128 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Luo, Maochao Zhou, Li Huang, Zhao Li, Bowen Nice, Edouard C. Xu, Jia Huang, Canhua Antioxidant Therapy in Cancer: Rationale and Progress |
title | Antioxidant Therapy in Cancer: Rationale and Progress |
title_full | Antioxidant Therapy in Cancer: Rationale and Progress |
title_fullStr | Antioxidant Therapy in Cancer: Rationale and Progress |
title_full_unstemmed | Antioxidant Therapy in Cancer: Rationale and Progress |
title_short | Antioxidant Therapy in Cancer: Rationale and Progress |
title_sort | antioxidant therapy in cancer: rationale and progress |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220137/ https://www.ncbi.nlm.nih.gov/pubmed/35740025 http://dx.doi.org/10.3390/antiox11061128 |
work_keys_str_mv | AT luomaochao antioxidanttherapyincancerrationaleandprogress AT zhouli antioxidanttherapyincancerrationaleandprogress AT huangzhao antioxidanttherapyincancerrationaleandprogress AT libowen antioxidanttherapyincancerrationaleandprogress AT niceedouardc antioxidanttherapyincancerrationaleandprogress AT xujia antioxidanttherapyincancerrationaleandprogress AT huangcanhua antioxidanttherapyincancerrationaleandprogress |